Potassium-channel opener in cardioplegia may restore coronary endothelial function

Annals of Thoracic Surgery

Volumn 66, Issue 4, 1998, Pages 1318-1322

  He, Guo Wei ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; APRIKALIM; BRADYKININ; CALCIMYCIN; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; N(G) NITROARGININE; POTASSIUM CHANNEL STIMULATING AGENT;

ANIMAL TISSUE; ARTERY ENDOTHELIUM; CARDIOPLEGIA; CONFERENCE PAPER; CONTROLLED STUDY; CORONARY ARTERY; FEMALE; HYPERKALEMIA; MALE; NONHUMAN; PRIORITY JOURNAL; VASOCONSTRICTION; VASODILATATION;

ANIMALS; BICARBONATES; CALCIUM CHLORIDE; CARDIOPLEGIC SOLUTIONS; CORONARY VESSELS; ENDOTHELIUM, VASCULAR; FEMALE; MAGNESIUM; MALE; PICOLINES; POTASSIUM CHANNELS; POTASSIUM CHLORIDE; PYRANS; SODIUM CHLORIDE; SWINE; VASODILATION; VASODILATOR AGENTS;

EID: 0032192064     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(98)00794-2     Document Type: Conference Paper

References (23)

1. 1. Hearse DJ, Braimbridge MV, Jynge P. Protection of the ischemic myocardium: cardioplegia. New York: Raven, 1981.
2. 2. Cohen NM, Wise RM, Wechsler AS, Damiano RJ. Elective cardiac arrest with a hyperpolarizing adenosine triphosphate-sensitive potassium channel opener. A novel form of myocardial protection? J Thorac Cardiovasc Surg 1993;106: 317-28.
3. 3. Cohen NM, Lederer WJ. Changes in the calcium current of rat heart ventricular myocytes during development. J Physiol (London) 1988;406:115-46.
4. + channel modulator aprikalim (RP 52891): improved cardioprotection in isolated ischemic rabbit hearts. Can J Physiol Pharmacol 1994;72:126-32.
5. 5. Sargent CA, Grover GJ, Antonaccio MJ, McCullough. The cardioprotective, vasorelaxant and electrophysiological profile of the large conductance calcium-activated potassium channel opener NS-004. J Pharmacol Exp Ther 1993;266: 1422-9.
6. 6. Grover GJ. Protective effects of ATP-sensitive potassium-channel openers in experimental myocardial ischemia. J Cardiovasc Pharmacol 1994;24:S18-27.
7. 7. Evora PRB, Pearson PJ, Schaff HV. Crystalloid cardioplegia and hypothermia do not impair endothelium-dependent relaxation or damage vascular smooth muscle of epicardial coronary arteries. J Thorac Cardiovasc Surg 1992;104: 1365-74.
8. 8. He G-W, Yang C-Q, Wilson GJ, Rebeyka IM. Tolerance of coronary endothelium and smooth muscle to hyperkalemia. Ann Thorac Surg 1994;57:682-8.
9. 9. He G-W, Yang C-Q, Rebeyka IM, Wilson GJ. Effect of neonatal endothelium and smooth muscle to hyperkalemic cardioplegic solutions. J Heart Lung Transplant 1995;14:92-101.
10. 10. Nilsson FN, Miller VM, Vanhoutte PM, McGregor CGA. Methods of cardiac preservation alter the function of the endothelium in porcine coronary arteries. J Thorac Cardiovasc Surg 1991;102:923-30.
11. 11. He G-W, Yang C-Q. Hyperkalemia alters endothelium-dependent relaxation through non-nitric oxide and non-cyclooxygenase pathway: a mechanism for coronary dysfunction due to cardioplegia. Ann Thorac Surg 1996;61: 1394-9.
12. 12. He G-W, Yang C-Q, Graier WF, Yang J-A. Hyperkalemia alters EDHF-mediated hyperpolarization and relaxation in porcine coronary arteries. Am J Physiol 1996;271(Heart Circ Physiol 40):H760-7.
13. 13. He G-W, Yang C-Q, Yang J-A. Depolarizing cardiac arrest and EDHF-mediated hyperpolarization and relaxation in coronary arteries: the effect and mechanism. J Thorac Cardiovasc Surg 1997;113:932-41.
14. 14. Quast U, Guillon JM, Cavero I. Cellular pharmacology of potassium channel openers in vascular smooth muscle. Cardiovasc Res 1994;28:805-10.
15. 15. He G-W, Yang C-Q. Superiority of hyperpolarizing to depolarizing cardioplegia on the EDHF-mediated relaxation. J Thorac Cardiovasc Surg 1997;114:643-50.
16. 16. He G-W, Angus JA, Rosenfeldt FL. Reactivity of the canine isolated internal mammary artery, saphenous vein, and coronary artery to constrictor and dilator substances: relevance to coronary bypass graft surgery. J Cardiovasc Pharmacol 1988;12:12-22.
17. 17. Hecker M, Bara AT, Bauersachs J, Busse R. Characterization of endothelium-derived hyperpolarizing factor as a cytochrome P450-derived arachidonic acid metabolite in mammals. J Physiol (London) 1994;481:407-14.
18. 18. Campbell WB, Gebremedhin D, Pratt PF, Harder DR. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res 1996;78:415-23.
19. 19. Feletou M, Vanhoutte PM. Endothelium-dependent hyperpolarization of canine coronary smooth muscle. Br J Pharmacol 1988;93:515-24.
20. 20. Chen G, Suzuki H, Weston AH. Acetylcholine releases endothelium-derived hyperpolarizing factor and EDRF from rat blood vessels. Br J Pharmacol 1988;95:1165-74.
21. 21. Holzmann S, Kukovetz WR, Windischhofer W, Paschke E, Graier WF. Pharmacologic differentiation between endothelium-dependent relaxations sensitive and resistant to Nitro-L-arginine in coronary arteries. J Cardiovasc Pharmacol 1994; 23:747-56.
22. 22. Brayden JE. Membrane hyperpolarization is a mechanism of endothelium-dependent cerebral vasodilation. Am J Physiol 1990;259(Heart Circ Physiol 28):H668-73.
23. 23. Cohen RA, Vanhoutte PM. Endothelium-dependent hyperpolarization. Beyond nitric oxide and cyclic GMP. Circulation 1995;92:3337-49.